Posts by: Diana Campelo Delgado

Diana Campelo Delgado

Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.

February 15, 2021February 15, 2021

Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

News

Seagen’s Tukysa (tucatinib) has been approved by the European Commission (EC) as part of a triple-combination therapy for people with previously treated advanced or metastatic HER2-positive breast cancer. The EC approved ... Read more

February 4, 2021February 4, 2021

Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors

News

Theralink Technologies announced that it has begun testing its new profiling biomarker assay — a test that could potentially provide oncologists with key information about a patient’s specific tumor — ... Read more

February 1, 2021February 1, 2021

US Study Enrolling Women to Help Determine Best Screening Practices

News

A national study is seeking women in the U.S. to help determine the safest and best way to screen for breast cancer, and to improve on current guidelines. It’s being ... Read more

January 14, 2021January 14, 2021

Genetic Test for Advanced Breast Cancer Launched in EU

News

Roche has launched a diagnostic genetic test to detect mutations in the PIK3CA gene in patients with advanced or metastatic breast cancer in the European Union. The cobas PIK3CA mutation test, performed ... Read more

January 11, 2021January 11, 2021

Breast Cancer Vaccine Cleared by FDA for Human Testing

News

A breast cancer vaccine can now be tested in human trials after its investigational new drug application was accepted by the U.S. Food and Drug Administration (FDA). A Phase 1 ... Read more

December 10, 2020December 10, 2020

‘Unassuming’ Non-medicinal Plant Can Stop Growth of Breast Cancer Cells, Study Shows

News

Scientists have discovered that an unassuming non-medicinal plant can stop the growth of human breast cancer cells without affecting non-cancerous cells. Their research into Arabidopsis thaliana, a small annual flowering plant ... Read more

October 26, 2020October 27, 2020

Adding Ibrance to Hormone Therapy Fails to Prolong Time Before Cancer Recurs, Trial Shows

News

Adding Ibrance (palbociclib) to standard endocrine therapy failed to prolong the time women with early hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative breast cancer lived without having their disease ... Read more